SCHEMBL12401100

SCHEMBL12401100

CC(C)C(NC(=O)OCc1cccnc1)C(=O)C(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
ELANE P08246 2/20 0.48
CTSL P07711 3/20 0.48
CTSB P07858 3/20 0.48
GPR132 Q9UNW8 2/20 0.47
NAMPT P43490 1/20 0.47
HDAC1 Q13547 1/20 0.46
FAAH O00519 1/20 0.45
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12331442 0.87 CYP3A4 (0.53) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL12330200 0.86 CYP3A4 (0.55) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL7269614 0.86 GPR132 (0.61) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL6447561 0.86 ALDH1A1 (0.55) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL6447557 0.86 ALDH1A1 (0.55) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL7269609 0.86 GPR132 (0.61) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL6446200 0.85 GPR132 (0.60) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL6446192 0.85 GPR132 (0.60) CYP3A4ALDH1A1LMNAMEN1MAPT
SCHEMBL14728306 0.85 CTSL (0.58) LMNAMEN1KMT2AELANECTSL
Lithium Ion SCHEMBL6446195 0.84 CYP3A4 (0.53) CYP3A4ALDH1A1LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575208-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 CYP3A4 219/4885ALDH1A1 1374/4885LMNA 2814/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 CYP3A4 219/4885ALDH1A1 1374/4885LMNA 2814/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 CYP3A4 527/4885ALDH1A1 2219/4885LMNA 1534/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CYP3A4 158/4885ALDH1A1 1255/4885LMNA 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.